Company intelligence / Profile preview

PellePharm

San Francisco, California, United Statesorpha.net ↗

Ownership: Private
Employees: ~1
Development stage: Phase 3

Overview

PellePharm has completed enrollment for a Phase 2 clinical trial in Gorlin Syndrome and was preparing to commence a pivotal Phase 3 trial in early 2019. Their topical patidegib gel has shown early promise in Phase 2 clinical studies for the mitigation of BCC tumors in Gorlin Syndrome.

Therapeutic areas: OncologyRare Diseases
Modalities: Small molecule inhibitorsTopical formulations
Industry: Biotech

Drug pipeline

1 asset

patidegib

Phase 3

Indications: Gorlin Syndrome, High Frequency Basal Cell Carcinoma

Partnerships

LEO Pharma

Beyond the preview

Go deeper on PellePharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PellePharm.

Explore the full profile